- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00898599
Prebiotics and Immune Function in Middle Aged Humans
Investigation of the Effects of a Prebiotic Supplement on Immune Function in Healthy Human Adults
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Prebiotics are naturally occurring carbohydrates found in a variety of edible plants. They are not digested by mammalian enzymes, and so reach the gut intact, where they are fermented by some species of intestinal bacteria. This fermentation is thought to have several benefits for the host including improving the immune response. Inulin-type fructans (oligofructose and inulin) are classified as prebiotics. Inulin is found naturally in significant amounts in a variety of plants foods, such as bananas, leeks, onions, artichokes, wheat and chicory. Synergy1 is a prebiotic preparation produced by Beneo-Orafti, and containing a mixture of oligofructose and inulin derived from chicory. Fructooligosaccharides including Synergy1 are widely used by the food industry and are commonly found as a source of insoluble fibre in many biscuit, bakery, cereal and dairy products.
There is increasing evidence that the changes in the intestinal microflora that occur with the consumption of fructooligosaccharides can modulate immune parameters, not only in the gut-associated lymphoid tissue, but also secondary lymphoid tissues and the peripheral circulation. Much of the evidence for beneficial effects of fructooligosaccharides on immune function comes from animal models e.g. rats, mice, dogs and pigs. Results from these studies show that the innate and adaptive immune systems of both the gut associated lymphoid tissue and the systemic immune system can be modified by fructooligosaccharides. However, there are few human studies so far which have investigated the effects of prebiotics on immune function, and these studies mostly rely on systemic markers of immunity. The results show little effect of fructooligosaccharides on innate immune function, but mixed results are reported regarding the adaptive immune system, suggesting that there may by improvement on this aspect of immunity with increased intake of fructooligosaccharides. The small number of published human studies led Watzl et al. (2005) to suggest that more human studies are needed to find out whether inulin and/or oligofructose have the potential to modulate systemic immunity in well-nourished individuals.
There are numerous methods available for assessing the human immune response. These have been evaluated by a panel of European experts (Albers et al. 2005). Based on its biological relevance, sensitivity and practical feasibility, response to vaccination was identified by this panel as the gold standard for measuring the functioning of the immune system in vivo (Albers et al. 2005). A small number of studies have studied the effect of fructooligosaccharides on the human immune response using vaccination response as the outcome, but only four of these examined fructooligosaccharides in the absence of other additional nutrients and of these two studies were in infants. Thus, the number of studies examining the immunologic impact of fructooligosaccharides in adult humans and using the gold standard outcome is very limited. From a public health perspective, it would be of importance, if fructooligosaccharides can improve immune function especially in older adults who are at risk of age-related immune decline. Thus, we propose to use a commercially available influenza vaccine (Imuvac®) to stimulate the immune response in healthy human adults, and to use this to assess the effect of a well defined prebiotic preparation commonly used in the food industry (Synergy1).
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studieorter
-
-
-
Southampton, Storbritannien, SO16 6YD
- University of Southampton
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Aged 45-65 years
- Body mass index 20 to 32 kg/m2.
- Not consuming probiotic supplements, yoghurts, drinks or other foods
- Not consuming prebiotic supplemented drinks or foods
- In general good health
- No antibiotic use in the 2 months prior to entering the study or during the study
- Not been vaccinated with the current season's influenza vaccine
- Being able to provide written informed consent
Exclusion Criteria:
- Aged < 45 or > 66 years
- Body mass index < 20 or > 32 kg/m2.
- Being diabetic (type 1 or type 2)
- Displaying manifestations of allergy - asthma, hay-fever, dermatitis - or being treated for these
- Being egg allergic
- Use of any prescribed medicine (unless deemed to be acceptable by the PI)
- Suffering from any infectious illness
- Chronic gastrointestinal problems (e.g. IBD, IBS, cancer)
- Recent blood donation
- Participation in another clinical trial
- Use of prebiotic or probiotic supplements, foods or drinks
- Consuming vitamin, mineral or oil supplements
- Previously vaccinated with the influenza vaccine being used.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: Maltodextrin
|
Maltodextrin som placebo
Andra namn:
|
|
Experimentell: Prebiotic
Inulin type fructooligosaccharides
|
Inulin type fructooligosaccharides
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Serum anti-vaccine antibody concentrations
Tidsram: Weeks 2 and 4 post-vaccination
|
Weeks 2 and 4 post-vaccination
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Serum total antibody (IgG, IgA, IgM) concentrations
Tidsram: Weeks -4, 0, 2 and 4 with respect to vaccination
|
Weeks -4, 0, 2 and 4 with respect to vaccination
|
|
Innate immune responses - neutrophil and monocyte phagocytosis and respiratory burst
Tidsram: Weeks -4, 0, 2 and 4 with respect to vaccination
|
Weeks -4, 0, 2 and 4 with respect to vaccination
|
|
Ex vivo T lymphocyte responses to mitogen (activation, proliferation and cytokine production)
Tidsram: Weeks -4, 0, 2 and 4 with respect to vaccination
|
Weeks -4, 0, 2 and 4 with respect to vaccination
|
|
Ex vivo T lymphocyte responses to vaccine (activation, proliferation and cytokine production)
Tidsram: Weeks 0, 2 and 4 with respect to vaccination
|
Weeks 0, 2 and 4 with respect to vaccination
|
|
Ex vivo natural killer cell activity
Tidsram: Weeks -4, 0, 2 and 4 with respect to vaccination
|
Weeks -4, 0, 2 and 4 with respect to vaccination
|
|
Faecal microflora
Tidsram: Weeks -4 and 0 with respect to vaccination
|
Weeks -4 and 0 with respect to vaccination
|
|
Salivary IgA concentration
Tidsram: Weeks -4, 0, 2 and 4 with respect to vaccination
|
Weeks -4, 0, 2 and 4 with respect to vaccination
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Philip C Calder, PhD, University of Southampton
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- RHMNUT0055
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .